Immunological control of β-amyloid levels in vivo
AssigneeBoston Biomedical Research Institute
InventorVictor Raso
Life of this patent
Estimating the term…
Abstract
Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a β-amyloid epitope. Also disclosed are methods for inhibiting the formation of β-amyloid plaques in the brain of a human, or promoting the disaggregation of a preformed β-amyloid plaque. Such methods recite the administration of a bispecific antibody.
Claims10
A therapeutic antibody that specifically binds and cleaves an epitope contained within amino acid positions 10-25 of β-amyloid, wherein said antibody binds soluble β-amyloid and soluble β-amyloid aggregates in a living organism.
An antibody fragment that specifically binds and cleaves an epitope contained within amino acid positions 10-25 of β-amyloid, wherein said antibody binds soluble β-amyloid and soluble β-amyloid aggregates in a living organism.
Dependencies are inferred from the claim text.